COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritisArticle Published on 2022-12-232023-07-08 Journal: Rheumatology (Oxford, England) [Category] COVID19(2023년), [키워드] biologics COVID-19 Epidemiology RA rituximab SARS-CoV-2 vaccination. [DOI] 10.1093/rheumatology/keac241 PMC 바로가기
Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional studyArticle Published on 2022-12-012022-11-15 Journal: Rheumatology International [Category] 바이오마커, 진단, [키워드] Active disease ANCA-associated vasculitis Care clinical manifestations Cohort conducted COVID-19 COVID-19 infection COVID-19 severity Critical cross-sectional Cyclophosphamide death demographic died Disease activity Features Follow-up General population Immunosuppressant increased risk India Infection managing moderate non-COVID-19 patient not differ ocular outcome Patient patients patients died predicted receiving regimen required risk of COVID-19 rituximab SARS-CoV-2. severity single-center Supplemental oxygen therapy the patient Treatment Univariate analysis Vasculitis [DOI] 10.1007/s00296-022-05177-2 PMC 바로가기
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension studyArticle Published on 2022-12-012023-07-10 Journal: Annals of the rheumatic diseases [Category] COVID19(2023년), [키워드] COVID-19 rituximab vaccination. [DOI] 10.1136/ard-2022-222579 PMC 바로가기
Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental doseArticle Published on 2022-12-012023-07-10 Journal: Clinical immunology (Orlando, Fla.) [Category] COVID19(2023년), [키워드] Autoimmune diseases B cells COVID-19 hypogammaglobinemia rituximab vaccination. [DOI] 10.1016/j.clim.2022.109144 PMC 바로가기
Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccinationArticle Published on 2022-12-012023-07-10 Journal: Journal of autoimmunity [Category] COVID19(2023년), [키워드] RA rituximab salivary antibodies. SARS-CoV-2 [DOI] 10.1016/j.jaut.2022.102918 PMC 바로가기
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodiesReview Published on 2022-12-012023-07-10 Journal: Virulence [Category] COVID19(2023년), [키워드] anti-CD20 COVID-19 rituximab SARS-CoV-2 vaccine. [DOI] 10.1080/21505594.2022.2146380 PMC 바로가기 [Article Type] Review
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic diseaseArticle Published on 2022-12-012023-07-11 Journal: RMD Open [Category] COVID19(2023년), [키워드] Arthritis, Rheumatoid Autoimmune diseases COVID-19 rituximab vaccination. [DOI] 10.1136/rmdopen-2022-002650 PMC 바로가기
B-cell repopulation dynamics and drug pharmacokinetics impact SARS-CoV-2 vaccine efficacy in anti-CD20-treated multiple sclerosis patientsArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95% CI 95% confidence interval Affect anti-CD20 anti-CD20 treatment antibody Antibody Response Antibody titers B cell B cells B-cell B-cell depletion Blood booster cellular response Cohort correlated detectable develop Efficacy Guidance humoral identify IgG^{+} interleukin-13 Logistic regression median memory multiple sclerosis naïve no correlation Odds ratio Patient patients predict predictor Probability recent rituximab S1 domain SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Seroconversion T-cell Response treated Treatment turn vaccination vaccination. vaccine responses [DOI] 10.1111/ene.15492 PMC 바로가기
Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as MechanismArticle Published on 2022-10-292022-11-15 Journal: Military Medicine [Category] 진단, [키워드] Activation acute respiratory syndrome adverse effect chilblains coronavirus COVID disease infusion interferon mechanism Pfizer presenting rituximab significantly skin lesion Toe Vaccine worsened [DOI] 10.1093/milmed/usab314 PMC 바로가기
Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based studyArticle Published on 2022-10-082022-11-15 Journal: BMC Neurology [Category] COVID19(2023년), SARS, 진단, [키워드] adjusted collected conducted Control control group COVID-19 General population greater Hospitalization Hospitalized individual Infection Multiple multiple sclerosis Patient patients positive COVID-19 Positive test Primary infection Reinfection required Retrospective study risk rituximab SARS-CoV-2 SARS-CoV-2 test SARS-CoV-2. severity statistically significant difference tested Two patient [DOI] 10.1186/s12883-022-02907-8 PMC 바로가기